Palliative treatment of painful disseminated bone metastases with 186Rhenium-HEDP in patients with lung cancer

Quarterly Journal of Nuclear Medicine and Molecular Imaging

Volumn 48, Issue 3, 2004, Pages 211-219

  Leondi, A H ^a,c   Souvatzoglou, M A ^a   Rapti, A S ^b   Leontopoulou, S A ^a   Papadaki, E K ^a   Datseris, I E ^a   Anagnostopoulou, U S ^b   Zerva, C J ^a  

^a ALEXANDRA HOSPITAL   (Greece)

^b SOTIRIA GENERAL HOSPITAL   (Greece)

^c NONE   (Greece)

Author keywords

Bone neoplasms; Lung neoplasms; Radionuclide imaging; Radiopharmaceuticals; Radiotherapy; Secondary

Indexed keywords

CISPLATIN; DOCETAXEL; ETIDRONIC ACID RE 186; GEMCITABINE; HYDROCORTISONE; OPIATE; TECHNETIUM 99M;

ADULT; AGED; ANALGESIA; ARTICLE; BONE MARROW TOXICITY; BONE METASTASIS; BONE PAIN; BONE SCINTISCANNING; CANCER PAIN; CANCER PALLIATIVE THERAPY; CLINICAL ARTICLE; COMPUTER ASSISTED TOMOGRAPHY; CONTRAST ENHANCEMENT; CONTROLLED STUDY; DISEASE EXACERBATION; DOSE RESPONSE; FEMALE; HUMAN; LUNG CANCER; MALE; NEPHROTOXICITY; OSTEOLYSIS; PAIN ASSESSMENT; PATIENT SATISFACTION; PATIENT SELECTION; QUALITY OF LIFE; SCORING SYSTEM; VISUAL ANALOG SCALE;

BONE NEOPLASMS; CARCINOMA; ETIDRONIC ACID; FEMALE; HUMANS; LUNG NEOPLASMS; MALE; MIDDLE AGED; ORGANOMETALLIC COMPOUNDS; PAIN; PALLIATIVE CARE; PATIENT SELECTION; RADIOPHARMACEUTICALS; TREATMENT OUTCOME;

EID: 8444244824     PISSN: 18244785     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (28)

1. Twyerors RG, Fairfield S. Pain in far advanced cancer. Pain 1982;14:303-10.
2. McEwan AJB. Unsealed source therapy of painful bone metastases: an update. Semin Nucl Med 1997;27:165-82.
3. Lewington VJ, Targeted radionuclide therapy for bone metastases. Eur J Nucl Med 1993;20:66-74.
4. Silberstein EB. Painful osteoblastic metastases: the role of nuclear medicine. Oncology 2001;15:157-63.
5. Lewington VJ. Cancer therapy using bone-seeking isotopes. Phys Med Biol 1996;41:2027-42.
6. Maxon HR, Deutch EA, Thomas SR, Libson K, Lukes SJ, Williams CC et al. Re-186(Sn)HEDP for treatment of multiple metastatic foci in bone: human biodistribution and dosimetric studies. Radiology 1988;166:501-7.
7. Maxon HR, Schroeder LE, Hertzberg VS, Thomas SR, Englaro EE, Samaratunga R et al. Rhenium-186(Sn)HEDP for treatment of painful osseous metastases: results of a double-blind crossover comparison with placebo. J Nucl Med 1991;32:1877-81.
8. Quirijnen JMSP, Han SH, Zonnenberg BA, de Klerk JM, van het Schip AD, van Dijk A et al. Efficacy of Rhenium-186-etidronate in prostate cancer patients with metastatic bone pain. J Nucl Med 1996;37:1511-5.
9. Graham MC, Scher HI, Liu GB, Yeh SD, Curley T, Daghighian F et al. Rhenium-186-labeled hydroxyethylidene diphosphonate dosimetry and dosing guidelines for the palliation of skeletal metastases from androgen-independent prostate cancer. Clin Cancer Res 1999;5:1307-18.
10. Blake GM, Zivanovic MA, McEwan AJ, Ackery DM. Strontium-89 therapy: strontium kinetics in disseminated carcinoma of the prostate. Eur J Nucl Med 1986;12:447-54.
11. de Klerk JM, van Dijk A, van het Schip AD, Zonnenberg BA, van Rijk PP. Pharmacokinetics of rhenium-186 after administration of rhenium-186-HEDP to patients with bone metastases. J Nucl Med 1992;33:646-51.
12. Ventafridda V, Sbanotto A, de Conno F. Pain in prostate cancer. Pall Med 1990;4:173-84.
13. Silberstein EB. Radiopharmaceutical therapy of osseous metastatic disease. In: Khalkhali I, Maublant JC, Goldsmith SJ, editors. Nuclear oncology diagnosis and therapy. Philadelphia: Lippincott Williams and Wilkins; 2000.p.104.
14. Roche E, Prentki M. Calcium regulation of immediate early response genes. Cell Calcium 1994;16:331-8.
15. Hellman S, Weichselbaum RR. Radiation oncology. JAMA 1994; 271:1712-4.
16. 186Re-etidronate in hormone resistant prostate cancer patients with painful bone metastases. Placebo Controlled Rhenium Study. J Nucl Med 2002;43:1150-6.
17. Quilty PM, Kirk D, Bolger JJ, Dearnaley DP, Lewington VJ, Mason MD et al. A comparison of the palliative effects of Strontium-89 and external beam radiotherapy in metastatic prostate cancer. Radiother Oncol 1994;31:33-40.
18. Rowbotham DJ. Endogenous opioids, placebo response and pain. Lancet 2001;357:1901-2.
19. Maxon HR 3rd, Thomas SR, Hertzberg VS, Schroder LE, Englaro EE, Samaratunga R et al. Rhenium-186-hydroxyethylidene diphosphonate for the treatment of painful bone metastases. Semin Nucl Med 1992;22:33-40.
20. Price DD, Bush FM, Long S, Harkins SW. A comparison of pain measurement characteristics of mechanical visual analogue and simple numerical rating scales. Pain 1994;56:217-26.
21. Mertens WC. Radionuclide therapy of bone metastases: prospects for enhancement of therapeutic efficacy. Semin Oncol 1993;20 Suppl 2:49-55.
22. de Klerk JM, Zonnenberg BA, Quirijnen JM, van bet Schip AD, van Dijk A, van Rijk PP. Re-186-HEDP palliation of painful bone metastases. Petten: Mallinckrodt Medical BV; 1992.
23. de Klerk JM, Zonnenberg BA, van bet Schip AD, van Dijk A, Han SH, Quirijnen JM et al. Dose escalation study of rhenium-186 hydroxyethylidene diphosphonate in patients with metastatic prostate cancer. Eur J Nucl Med 1994;21:1114-20.
24. Silberstein EB. Dosage and response in radiopharmaceutical therapy of painful osseous metastases. J Nucl Med 1996;37:249-52.
25. Israel O, Keidar Z, Rubinov R, Iosilevski G, Frenkel A, Kuten A et al. Quantitative bone SPECT for prediction of pain relief in metastatic bone disease treated with Rhenium-186 Etidronate. J Clin Oncol 2000;18:2747-54.
26. Tu SM, Milikan RE, Mengistu B, Amato RJ, Pagliaro LC, Daliani D et al. Bone-targeted therapy for advanced androgen-independent carcinoma of the prostate: a randomized phase II trial. Lancet 2001;357:336-41.
27. McCready VR, O'Sullivan JM. Future directions for unsealed source radionuclide therapy for bone metastases. Eur J Nucl Med 2002;29:1271-5.
28. Geldof A, Plaizier M, Duivenvoorden I, Ringelberg M, Versteegh R, Newling D et al. Cell cycle perturbations and radiosensitization effects in a human prostate cancer cell line. J Cancer Res Clin Oncol 2003;129:175-82.